Effect of endothelin receptor antagonist bosentan on plasma leptin concentration in acute myocardial infarction in rats

Pathophysiology

Volumn 9, Issue 4, 2003, Pages 249-256

  Ostrowski, Robert P ^a   Januszewski, Sławomir ^a   Kowalska, Zdzisława ^a   Kapuściński, Andrzej ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Bosentan; Receptors

Indexed keywords

ANTIGEN; BOSENTAN; CARBON DIOXIDE; CHLORAL HYDRATE; ENDOTHELIN RECEPTOR ANTAGONIST; FORMALDEHYDE; IODINE 125; LEPTIN; TRIPHENYLTETRAZOLIUM;

ACUTE HEART INFARCTION; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; BLOOD PRESSURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DESCENDING AORTA; DISEASE COURSE; DRUG EFFECT; ELECTROCARDIOGRAM; FEEDING; HEART INFARCTION SIZE; HEART RATE; IMMERSION; LEFT CORONARY ARTERY; MALE; MEASUREMENT; MICROSCOPY; MONITORING; MORPHOMETRICS; MORTALITY; NONHUMAN; OXYGEN TENSION; PERFUSION; PH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RAT; RAT STRAIN; STAINING; THORACOTOMY;

EID: 0142090878     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(03)00028-2     Document Type: Article

References (50)

1. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425-432.
2. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 22:1998;1145-1158.
3. Haffner S.M., Mykkanen L., Rainwater D.L., Karhapaa P., Laakso M. Is leptin concentration associated with the insulin resistance syndrome in nondiabetic men? Obes. Res. 7:1999;164-169.
4. Bouloumie A., Marumo T., Lafontan M., Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 13:1999;1231-1238.
5. Parhami F., Tintut Y., Ballard A., Fogelman A.M., Demel L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ. Res. 88:2001;954-960.
6. Nickola M.W., Wold L.E., Colligan P.B., Wang G.J., Samson W.K., Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension. 36:2000;501-505.
7. Cleland S.J., Sattar N., Petrie J.R., Forouchi N.G., Elliott H.L., Connell J.M.C. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin. Sci. 98:2000;531-535.
8. Soderberg S., Ahren B., Jansson J.H., Johnson O., Hallmans G., Asplund K., Olsson T. Leptin is associated with increased risk of myocardial infarction. J. Intern. Med. 246:1999;409-418.
9. Soderberg S., Ahren B., Stegmayr B., Johnson O., Wiklund P.G., Weinehall L., Hallmans G., Olsson T. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 30:1999;328-337.
10. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A., Sattar N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 104:2001;3052-3056.
11. Meisel S.R., Ellis M., Pariente C., Pauzner H., Liebowitz M., David D., Shimon I. Serum leptin levels increase following acute myocardial infarction. Cardiology. 95:2001;206-211.
12. Xiong Y., Tanaka H., Richardson J.A., Williams S.C., Slaughter C.A., Nakamura M., Chen J.L., Yanagisawa M. Endothelin-1 stimulates leptin production in adipocytes. J. Biol. Chem. 276:2001;28471-28477.
13. Sakai S., Yorikane R., Miyauchi T., Sakurai T., Kasuya Y., Yamaguchi I., Sugishita Y., Goto K. Altered production of endothelin-1 in the hypertrophied rat heart. J. Cardiovasc. Pharmacol. 26:(Suppl. 3):1995;452-455.
14. Tonnessen T., Christensen G., Oie E., Holt E., Kjekshus H., Smiseth O.A., Sejersted O.M., Attramadal H. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiovasc. Res. 33:1997;601-610.
15. Sakai S., Miyauchi T., Sakurai T., Yamaguchi I., Kobayashi M., Goto K., Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin-receptor antagonist. Increased expression on endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J. Am. Coll. Cardiol. 28:1996;1580-1588.
16. Huntington K., Picard P., Moe G., Stewart D.J., Albernaz A., Monge J.C. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure. J. Cardiovasc. Pharmacol. 31:1998;424-426.
17. Picard P., Smith P.J., Monge J.C., Rouleau J.L., Nguyen Q.T., Calderone A., Stewart D.J. Coordinated upregulation of the cardiac endothelin system in the rat model of heart failure. J. Cardiovasc. Pharmacol. 31:1998;294-297.
18. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., Morton J.J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
19. Rodeheffer R.J., Lerman A., Heublein D.M., Burnett J.J. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin. Proc. 67:1992;719-724.
20. Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G., Brandt R.R., Wright S., Heublein D.M., Kao P.C., Edwards W.D., Burnett J.C. Jr. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
21. Tuinenburg A.E., Van Veldhuisen D.J., Boomsma F., Van Den Berg M.P., De Kam P.J., Crijns H.J. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am. J. Cardiol. 81:1998;1207-1210.
22. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
23. Lerman A., Kubo S.H., Tschumperlin L.K., Burnett J.C. Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J. Am. Coll. Cardiol. 20:1992;849-853.
24. Tsutamoto T., Hisanaga T., Fukai D., Wada A., Maeda Y., Maeda K., Kinoshita M. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am. J. Cardiol. 76:1995;803-808.
25. Krum H., Goldsmith R., Wilshire-Clement M., Miller M., Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am. J. Cardiol. 75:1995;1282-1283.
26. Fukuchi M., Giaid A. Expression of endothelin-1 and endothelin- converting enzyme-1 mRNAs and proteins in failing human hearts. J. Cardiovasc. Pharmacol. 31:1998;421-423.
27. Zolk O., Quattek J., Sitzler G., Schrader T., Nickenig G., Schnabel P., Shimada K., Takahashi M., Böhm M. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 99:1999;2118-2123.
28. Pacher R., Stanek B., Hülsmann M., Koller-Strametz J., Berger R., Schuller M., Hartter E., Ogris E., Frey B., Heinz G., Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evolution in severe heart failure. J. Am. Coll. Cardiol. 27:1996;633-641.
29. Pacher R., Bergler-Klein J., Globits S., Teufelsbauer H., Schuller M., Krauter A., Ogris E., Rodler S., Wutte M., Hartter E. Plasma big endothelin-1 concentrations in congestive heart failure with or without systemic hypertension. Am. J. Cardiol. 71:1993;1293-1299.
30. Pousset F., Isnard R., Lechat P., Kalotka H., Carayon A., Maistre G., Escolano S., Thomas D., Komajda M. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur. Heart J. 18:1997;254-258.
31. Hulsmann M., Stanek B., Frey B., Sturm B., Putz D., Kos T., Berger R., Woloszczuk W., Maurer G., Pacher R. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J. Am. Coll. Cardiol. 32:1998;1695-1700.
32. Clozel M., Breu V., Gray G.A., Kalina B., Löffler B., Burri K., Cassal J., Hirth G., Müller M., Neidhart W., Ramuz H. Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
33. Fraccarollo D., Hu K., Galuppo P., Gaudron P., Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 96:1997;3963-3973.
34. Mulder P., Richard V., Derumeaux G., Hogie M., Henry J.P., Lallemand F., Compagnon P., Mace B., Comoy E., Letac B., Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 96:1997;1976-1982.
35. Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N. Engl. J. Med. 338:1998;784-790.
36. Teerlink J.R., Loffler B.M., Hess P., Maire J.P., Clozel M., Clozel J.P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 89:1994;2510-2518.
37. Wenzel R.R., Fleisch M., Shaw S., Noll G., Kaufmann U., Schmitt R., Jones C.R., Clozel M., Meier B., Luscher T.F. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery diseases. Circulation. 98:1998;2235-2240.
38. Kiowski W., Sütsch G., Hunziker P., Muller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
39. Sütsch G., Kiowski W., Yan X.-W., Hunziker P., Christen S., Strobel W., Kim J.H., Rickenbacher P., Bertel O. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 98:1998;2262-2268.
40. Johns T.N.P., Olson B.J. Experimental myocardial infarction. Ann. Surg. 140:1954;675-682.
41. Selye H., Bajusz E., Grasso S., Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology. 11:1960;5398-5407.
42. Maclean D., Fishbein M.C., Braunwald E., Maroko P.R. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J. Clin. Invest. 61:1978;541-551.
43. Pfeffer M.A., Pfeffer J.M., Fishbein M.C., Fletcher P.J., Spadaro J., Kloner R.A., Braunwald E. Myocardial infarct size and ventricular function in rats. Circ. Res. 44:1979;503-512.
44. Wu D., Stassen J.M., Seidler R., Doods H. Effects of BIIB513 on ischemia-induced arrhythmias and myocardial infarction in anesthetized rats. Basic Res. Cardiol. 95:2000;449-456.
45. Quehenberger P., Exner M., Sunder-Plassmann R., Ruzicka K., Bieglmayer C., Endler G., Muellner C., Speiser W., Wagner O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res. 90:2002;711-718.
46. Packer M., Caspi A., Charlon V. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial. Circulation. 98:(Suppl. S):1998;12.
47. Schwarz E.R., Somoano Y., Hale S.L., Kloner R.A. What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat? J. Thromb. Thrombolysis. 10:2000;181-187.
48. Watanabe T., Awane Y., Ikeda S., Fujiwara S., Kubo K., Kikuchi T., Kusumoto K., Wakimasu M., Fujino M. Pharmacology of non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br. J. Pharmacol. 114:1995;949-954.
49. Kojima M., Kusumoto K., Fujiwara S., Watanabe T., Fujino M. Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist, TAK-044. J. Cardiovasc. Pharmacol. 26:(Suppl. 3):1995;S365-S368.
50. Sakai S., Miyauchi T., Sakurai T., Kasuya Y., Ihara M., Yamaguchi I., Goto K., Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation. 93:1996;1214-1222.